Survival benefit with salvage radiotherapy for patients with locoregionally recurrent extranodal NK/T cell lymphoma, nasal type
The purposes of this study are to evaluate prognosis in patients with locoregionally recurrent extranodal nasal-type NK/T cell lymphoma (NKTCL) and to determine the value of salvage radiotherapy.Forty-two patients with NKTCL who developed first locoregional recurrence with (n=13) or without (n=29) systemic failure were reviewed.Retreatment included chemotherapy (n=20), radiotherapy (n=13), and radiotherapy plus chemotherapy (n=9).Fifteen patients were reirradiated for localized recurrent disease.The 5-year overall survival (OS) rate after recurrence was 40 %, with a median survival of 26 months.The 2-year OS rate and median OS were 68 % and 36 months for locoregional recurrence only, compared with 31% and 14 months for both locoregional and systemic recurrence, respectively (p=0.034).Subgroup analysis for patients with localized recurrent disease revealed an improved OS with radiotherapy.The 2-year and 5-year OS rates were 77 and 69 % for radiotherapy, respectively, compared with a 2-year OS rate of 50 % and median OS of 16 months for chemotherapy alone (p=0.006).Patients with localized recurrence had a better prognosis than those with systemic recurrence.Salvage radiotherapy or reirradiation resulted in a favorable prognosis for patients with localized recurrent disease.
Chemotherapy Locoregional recurrence NK/T cell lymphoma Prognosis Radiotherapy Reirradiation
Ting Zhao Hua Ren Bo Chen Shu-Nan Qi Qing-Feng Liu Ning-Ning Lu Zi-Hao Yu Ye-Xiong Li Shu-Lian Wang Jing Jin Wei-Hu Wang Yong-Wen Song Yue-Ping Liu Xin-Fan Liu Hui Fang
Department of Radiation Oncology, Cancer Hospital and Institute, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100021, People”s Republic of China
国内会议
北京
英文
194-203
2014-01-11（万方平台首次上网日期，不代表论文的发表时间）